Across the recent three months, 6 analysts have shared their insights on Genmab (NASDAQ:GMAB), expressing a variety of opinions spanning from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 1 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 3 | 1 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $49.67, a high estimate of $50.00, and a low estimate of $48.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 0.16%.
Exploring Analyst Ratings: An In-Depth Overview
The standing of Genmab among financial...
Login or create a forever free account to read this news
Sign up/Log in